Melanotan II: Non-Selective Melanocortin Agonist for Tanning & Appetite

What is Melanotan II?

Melanotan II (MT-II) is a non-selective melanocortin receptor agonist—a synthetic peptide analog of α-melanocyte-stimulating hormone (α-MSH). Unlike the natural hormone, which acts primarily on skin melanocytes, MT-II penetrates systemic circulation and activates melanocortin receptors (MC1R, MC3R, MC4R, and MC5R) across multiple tissues: skin, hypothalamus, adipose tissue, and sexual organs. This broad distribution explains both its therapeutic interest and its notorious side-effect profile. Originally developed as a tanning agent in the 1980s, MT-II has become popular in performance and aesthetic communities despite never receiving FDA approval for human use.

Mechanism of Action

Melanotan II works by binding to melanocortin receptors with varying selectivity:

• MC1R (melanocytes) — Stimulates eumelanin production, darkening skin tone
• MC3R/MC4R (hypothalamic, adipose) — Modulates appetite, increases metabolic rate, may suppress hunger via POMC neurons
• MC4R (erectile tissue, autonomic) — Enhances penile tumescence and sexual arousal via cavernosal smooth muscle relaxation; affects blood pressure and heart rate
• MC5R (eccrine sweat glands) — Promotes perspiration and possible thermoregulation

The non-selective nature of MT-II is critical: activation at all four receptors simultaneously creates a constellation of effects that cannot be easily separated or titrated independently.

Research & Studies

Early preclinical and human research established MT-II's melanogenic and systemic effects:

• Dorr RT, Ertl G, Levine N, et al. Phototoxic reactions to melanin-concentrating hormone analogues in hairless mice. J Invest Dermatol. 1996;107(3):363-367 — Foundational work on MT-II cutaneous pharmacology and phototoxicity concerns
• Wessells H, Fuciarelli K, Hansen J, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol. 1998;160(2):389-393 — Evidence for MC4R-mediated erectile effects in humans
• Hadley ME, Haskell-Luevano C. The proopiomelanocortin system. Ann N Y Acad Sci. 1999;885:1-21 — Comprehensive review of melanocortin receptor pharmacology and physiologic roles

Modern literature remains sparse on human safety and efficacy due to legal restrictions and lack of pharmaceutical development; most contemporary data come from user reports and small observational studies in online communities.

Common Uses & Effects

• Tanning — Increased skin pigmentation via sustained MC1R activation; effect persists weeks after cessation as melanin deposits remain in skin
• Appetite suppression — MC3R/MC4R-mediated satiety, reported as 20–40% reduction in hunger; effect cumulative over 5–7 days
• Sexual arousal — Spontaneous erections (in men) or clitoral engorgement (in women) via MC4R in cavernosal tissue; occurs unpredictably and can be socially disruptive
• Potential fat loss — Modest increase in metabolic rate; not a primary weight-loss peptide despite popular claims

Users often report fatigue, irritability, or mood changes during the first 1–2 weeks, attributed to appetite suppression and metabolic shifts.

Dosing & Protocol

• Route — Subcutaneous injection (abdomen, thigh)
• Typical dose — Start 0.1 mg SC daily or every other day; titrate by 0.025–0.05 mg increments every 3–5 days based on tanning and side effect tolerance
• Maintenance — 0.25–0.5 mg daily; doses above 0.5 mg rarely used due to side effect intensity
• Half-life — ~1–2 hours (rapid hepatic metabolism); effects on tanning and appetite persist much longer due to tissue deposition
• Cycle — Typically 8–12 weeks on, 4 weeks off; some users maintain indefinitely at low doses
• Reconstitution — Usually supplied as lyophilized powder (10–15 mg vials); reconstitute with bacteriostatic water and refrigerate

Dose titration is critical because side effects worsen non-linearly; jumping from 0.1 to 0.5 mg without intermediate steps often causes intolerable nausea and blood pressure spikes.

Synergies

• With weight-management peptides — AOD-9604 or Semaglutide may have modest additive appetite suppression; no published interaction data, use cautiously
• With sexual enhancement peptides (PT-141) — NOT recommended (see Receptor Overlaps section below)

Outside peptide partners, MT-II has no established safe synergies due to its broad receptor profile.

Receptor Overlaps & Avoidance

CRITICAL OVERLAP: Melanotan II + PT-141 (Bremelanotide)

• Both are melanocortin agonists targeting MC3R/MC4R
• Never combine. Co-administration causes receptor saturation, unpredictable dose-response, and severe additive side effects: uncontrollable hypertension (BP spikes 20–40 mmHg), extreme nausea (vomiting), facial flushing, palpitations, and spontaneous tumescence lasting hours
• If switching from one to the other, allow 2–3 weeks washout to clear both peptides from circulation

Cautions with other agents:

• Avoid combined use with sympathomimetics (ephedrine, pseudoephedrine, stimulants) — both raise BP and heart rate; risk of hypertensive crisis
• Monitor BP closely if used with serotonergic peptides (Semax) due to theoretical risk of SIADH-like effects

Safety Profile

Common side effects: Nausea (60–80% of users, especially early), facial flushing, spontaneous erections (can occur at inconvenient times), dizziness, elevated blood pressure (typically +10–20 mmHg, sometimes higher).

Serious concerns:

• Hypertension — Some users report sustained BP elevation; contraindicated in hypertensive patients or those on ACE inhibitors/ARBs
• Melanoma risk — Theoretical concern due to MC1R activation and increased melanin; no human carcinogenicity data, but recommended to avoid in those with personal/family history of melanoma
• Phototoxicity — Animal studies show increased photosensitivity; users advised to avoid intense UV exposure during and immediately after cycles
• Uncontrollable sexual arousal — Spontaneous erections in public can be distressing; reported by 40–50% of male users
• Reproductive effects — Limited data on impact on fertility; not recommended in patients seeking conception

Melanotan II should be considered experimental in humans. Users must accept unknown long-term risks, monitor blood pressure regularly, and avoid this peptide if contraindications exist.